Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 31;10(4):e0062122.
doi: 10.1128/spectrum.00621-22. Epub 2022 Jun 15.

Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates

Jaclyn A Cusumano  1 , Ruhma Khan  2 , Zeel Shah  2 , Cassie Philogene  1 , Amrita Harrichand  1 , Vanthida Huang  3
Affiliations

Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates

Jaclyn A Cusumano et al. Microbiol Spectr. .

Abstract

Penicillin plus ceftriaxone is a promising alternative to ampicillin plus ceftriaxone for the treatment of Enterococcus faecalis infective endocarditis. Limited data is available supporting the utilization of penicillin plus ceftriaxone. A total of 20 E. faecalis isolates; one wild-type strain (JH2-2) and 19 clinical blood strains were assessed for penicillin plus ceftriaxone and ampicillin plus ceftriaxone synergy using a 24-h time-kill experiment. Susceptibility was determined by broth microdilution. Differences in bactericidal, bacteriostatic, or inactivity, as well as synergy between treatments were assessed by chi-square or Fisher exact test. All E. faecalis isolates were considered susceptible to ampicillin and penicillin. Ampicillin plus ceftriaxone versus penicillin plus ceftriaxone similarly demonstrated synergy. Bactericidal activity was more commonly observed for ampicillin plus ceftriaxone versus penicillin plus ceftriaxone. Among isolates with a penicillin MIC of 4 μg/mL (n = 7), synergistic activity for both combinations was less common compared to isolates with a penicillin MIC ≤ 2 μg/mL (n = 13). Ampicillin plus ceftriaxone and penicillin plus ceftriaxone demonstrate similar synergistic potential against E. faecalis clinical blood isolates, but strains with higher penicillin and ceftriaxone MICs less frequently demonstrated synergy. Further research is warranted to determine the role of the penicillin plus ceftriaxone therapy and the penicillin MIC in clinical practice. IMPORTANCE Penicillin plus ceftriaxone demonstrates similar synergistic activity against Enterococcus faecalis to ampicillin plus ceftriaxone. Isolates with a penicillin MIC of 4 mg/L and a ceftriaxone MIC of 512 or higher, lack penicillin plus ceftriaxone synergy despite the penicillin susceptibility MIC breakpoint of 8 mg/L.

Keywords: Enterococcus faecalis; ampicillin; ceftriaxone; penicillin; synergy.

PubMed Disclaimer

Conflict of interest statement

The authors declare a conflict of interest. J.A.C. has served as an advisor for Shionogi. All other authors declare no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Fernandez-Hidalgo N, Almirante B, Gavalda J, Gurgui M, Pena C, de Alarcon A, Ruiz J, Vilacosta I, Montejo M, Vallejo N, Lopez-Medrano F, Plata A, Lopez J, Hidalgo-Tenorio C, Galvez J, Saez C, Lomas JM, Falcone M, de la Torre J, Martinez-Lacasa X, Pahissa A. 2013. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis 56:1261–1268. doi:10.1093/cid/cit052. - DOI - PubMed
    1. Pericàs JM, Llopis J, Muñoz P, Gálvez-Acebal J, Kestler M, Valerio M, Hernández-Meneses M, Goenaga MÁ, Cobo-Belaustegui M, Montejo M, Ojeda-Burgos G, Sousa-Regueiro MD, de Alarcón A, Ramos-Martínez A, Miró JM, Sánchez FF, Noureddine M, Rosas G, de la Torre Lima J, Blanco R, Boado MV, Campaña Lázaro M, Crespo A, Goikoetxea J, Iruretagoyena JR, Irurzun Zuazabal J, López-Soria L, Montejo M, Nieto J, Rodrigo D, Rodríguez R, Vitoria Y, Voces R, García López MV, Georgieva RI, Ojeda G, Rodríguez Bailón I, Ruiz Morales J, María Cuende A, Echeverría T, Fuerte A, Gaminde E, Goenaga MÁ, Idígoras P, Antonio Iribarren J, Izaguirre Yarza A, Kortajarena Urkola X, Reviejo C, Carrasco R, Climent V, et al. . 2020. A contemporary picture of enterococcal endocarditis. J Am Coll Cardiol 75:482–494. doi:10.1016/j.jacc.2019.11.047. - DOI - PubMed
    1. Kim D, Lee H, Yoon EJ, Hong JS, Shin JH, Uh Y, Shin KS, Shin JH, Kim YA, Park YS, Jeong SH. 2019. Prospective observational study of the clinical prognoses of patients with bloodstream infections caused by ampicillin-susceptible but penicillin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 63. doi:10.1128/AAC.00291-19. - DOI - PMC - PubMed
    1. Contreras GA, Munita JM, Simar S, Luterbach C, Dinh AQ, Rydell K, Sahasrabhojane PV, Rios R, Diaz L, Reyes K, Zervos M, Misikir HM, Sanchez-Petitto G, Liu C, Doi Y, Abbo LM, Shimose L, Seifert H, Gudiol C, Barberis F, Pedroza C, Aitken SL, Shelburne SA, van Duin D, Tran TT, Hanson BM, Arias CA. 2022. Contemporary clinical and molecular epidemiology of vancomycin-resistant enterococcal bacteremia: a prospective multicenter cohort study (VENOUS I). Open Forum Infect Dis 9:ofab616. doi:10.1093/ofid/ofab616. - DOI - PMC - PubMed
    1. Hollenbeck BL, Rice LB. 2012. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence 3:421–433. doi:10.4161/viru.21282. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources